Abstract Desmosine (DES) is an elastin-derived, cross-link amino acid, which is not metabolized; hence, its urinary levels re£ect elastin breakdown.We hypothesized that elastin degradation should increase as a result of increased lung in£ammation during an acute exacerbation of COPD and should decrease after recovery.To testthis hypothesis we measured DES in three urine samples from nine COPD subjects during the ¢rst 5 days of an acute exacerbation and at 2 months after recovery.We also measured forced expiratory volume in 1 sec (FEV 1 ) to monitor the e¡ects of the exacerbation on ventilatory function.The mean (SD) FEV 1 was 45 (15)% predicted during the exacerbation and 57?8 (16)% predicted 2 monthslater (P=0?00001).The mean (SD) DES excretion was 25 Á3 (9) mg g -1 creatinine at day1;23 Á5 (9) atday 3 and 24 (9) at day 5 of the exacerbation.The mean (SD) urinary DES excretion 60 days after discharge was 20?9 (7) mg g -1 creatinine (P=0?049) in comparison with the mean of the three acute-phase values.The size of the increase in desmosine excretion during exacerbation is small, 3?2mg g -1 creatinine or 16% of the recovery desmosine value.We conclude that there is a small but statistically signi¢cant increase in lung elastin breakdown in the body during an acute exacerbation of COPD.r
INTRODUCTION
Chronic obstructive pulmonary disease (COPD) is a destructive lung disorder characterized by chronic, partly reversible air£ow limitation and the presence of chronic bronchitis or emphysema. Degradation of extracellular matrix components, mainly elastin, due to an imbalance between proteinases and their naturally occurring inhibitors is a key pathological feature of emphysema (1) . Excess elastin degradation in the body results in excretion in the urine of the elastin-derived amino acids, desmosine (DES) (2) . This cross-linked amino acid is unique to mature elastin and is not metabolized in the body. Urinary excretion of DES has been reported to be higher in patients with COPD, and in current smokers with normal lung function (3, 4) than in never-smoking controls.
We recently applied a new separation technique, highperformance capillary electrophoresis (HPCE), in its micellar electrokinetic chromatographic (MEKC) modality, to the quanti¢cation of urinary DES in subjects with a variety of chronic destructive lung diseases, including subjects with COPD, disseminated bronchiectasis of unknown origin, pulmonary emphysema associated with inherited de¢ciency of a 1 -anti-trypsin (AAT) and cystic ¢brosis (4) .
In a preliminary study, we noted that COPD patients with exacerbations excreted more elastin cross-links than patients with stable COPD (4) . We reasoned that elastin degradation increased due to increased in£amma-tion in the lungs during an acute exacerbation of COPD, which resulted in increased urinary DES excretion. If this were so, urinary DESvalues should decrease after recovery from the exacerbation. To test this hypothesis we collected three urine samples from each of nine COPD subjects during the ¢rst 5 days of an acute exacerbation and we collected a fourth urine sample at 2 months after recovery.We also measured forced expiratory volume in 1 sec (FEV 1 ) serially during the study to monitor the e¡ects of the exacerbation on ventilatory function. Our study shows a small, but statistically signi¢cant decrease in urinary DES excretion at 2 months, in comparison with values during the acute exacerbation.This is accompanied by a signi¢cant increase in FEV 1 at 2 months compared to the acute exacerbation.
MATERIALS AND METHODS

Design of the study
This investigation was designed as a longitudinal study, which was approved by the hospital's Ethical Committee. All patients gave their informed consent prior to entering the study.
Patients
We enrolled nine consecutive patients admitted to the Clinica di Malattie dell'Apparato Respiratorio, San Matteo Hospital, because of acute exacerbation of COPD. These subjects belong to a cohort of patients regularly seen in the outpatient clinic of the same department, in whom the diagnosis of COPD had been previously established according to ATS criteria (5). All patients were male former smokers.
De¢nition of exacerbation and selection of patients
Following the criteria of Anthonisen et al. (6), we diagnosed an acute exacerbation of COPD by the presence of two or three of the symptoms of increased dyspnoea, increased sputum volume and development of sputum purulence. The initial assessment of patients was performed in the emergency room (ER) of San Matteo Hospital. In our study we enrolled only patients admitted because of a moderately severe exacerbation, thus excluding patients with a mild exacerbation who were immediately discharged from the ER and treated at home. We also excluded those with a severe exacerbation, requiring mechanical or non-invasive ventilation (7) . Patients who had had another episode of acute exacerbation within the previous three months or had already received oral corticosteroids at the time of admission were excluded from the study.
Patients'assessment and treatment
At the time of hospitalization, the patients were submitted to routine assessment, including blood gas analysis, chest X-ray (to exclude pneumonia) and sputum culture. The patients received aminophylline every 12 h, methylprednisolone 30 mg every 24 h i.v., nebulizations of oxitropium bromide and beclomethasone every 8 h, low £ow oxygen supplementation via nasal cannula and an 8 -day course of oral amoxycillin/clavulanic acid 1 g every 12 h (in one case the antibiotic therapy was changed to i.v. cefotaxime 1 g every 12 h after 48 h because of isolation from sputum of K. pneumoniae resistant to amoxycillin/clavulanic acid). All associated conditions were treated appropriately. Pulmonary functions tests were performed as soon as the general and respiratory condition of the patients allowed, but in all cases within the ¢rst 4 days of the hospital admission. Table 1 reports the clinical characteristics of the patients enrolled in the study.
Outcome ofthe exacerbation and follow-up
The patients'discharge was decided on the basis of remission of symptoms and signs used to de¢ne the episode of exacerbation. Still-needed treatments were swithched from the intravenous to the oral route; oral methylprednisolone was tapered and de¢nitively withdrawn within 3 weeks after discharge. All patients were telephoned every 2 weeks to inquire about their condition. A follow-up examination was performed 60 days after discharge. Stability of their respiratory state was checked by a brief questionnaire and pulmonary function tests were performed.
Timing of urine collection
Three urine samples were collected during the hospitalization: one within the ¢rst 24 h (T 1 ), the others on the third (T 3 ) and ¢fth (T 5 ) days. At the 2-month follow-up visit, patients delivered a urine sample collected during the 12 h prior to the appointment (T 60 ). (5) 164 (7) 71 (5) 35 (7) 45 (5) 59 (2) *Data are expressed as mean (SD). Six subjects had three ofthe de¢ning symptoms of an exacerbation (6); three subjects had two of the three symptoms.
w Post-bronchodilator data obtained within the fourth day of hospitalization.
Biochemical evaluation
Chemicals
Sodium phoshate (used as a background electrolyte) was purchased from Bio-Rad (Richmond, CA, U.S.A). Doubly distilled water was obtained from a Millipore (Bedford, MA, U.S.A.) Milli-Q puri¢cation system. All other chemicals were of analytical grade and were used without further puri¢cation.
Urine collection and treatment
Urine samples were collected into sterile plastic bottles, starting in the morning, until a volume of100 ml was obtained, which was stored at À201C until processed. Each sample was concentrated under reduced pressure using a heated rotary evaporator (501C). A sample of urine (0?8 ml) was then ultracentrifuged at room temperature with microconcentrators Microcon 30 (Millipore) and transferred to hydrolysis pyrex tubes, evaporated to dryness and hydrolysed in vacuo with HCI 6 N at 1061C for 24 h. Hydrolysed samples were lyophilized and the residue dissolved in deionised water (repeated twice in order to remove HCI totally). Finally, samples were taken up with 0?4 ml of distilled water and submitted to HPCE. The content of DES was expressed as mg g -1 creatinine.
Capillary electrophoretic instrumentation and running conditions
All runs were performed using a Bio-Rad Biofocus 3000 system equipped with a high-speed UV-Vis scanning detector. Fused silica capillaries of 57 cm (50 cm e¡ective length from inlet to detector) Â 50 mm ID were obtained from Beckman (Palo Alto, CA, U.S.A.). The procedure followed was essentially as described previously (8), with the modi¢cation subsequently adopted (4).
Statistical analysis
Data are presented as mean and standard deviation (SD). Normality of data distribution was assessed by the Shapiro^Wilk test. Repeated measure MANOVA was used to test for statistically signi¢cant changes over time for DES and t-test for paired data of FEV 1 . A P-value of less than 0?05 was considered to be statistically signi¢cant. All tests were two-sided. Analyses were performed by the software STATA (StataCorp, 1999. Stata Statistical Software release 6?0 College Station,TX, U.S.A.).
RESULTS
Urinary excretion of elastin cross-links changed little during the ¢rst 5 days of hospital admission: mean (SD) DES excretion was 25?3 (9) mg g -1 creatinine at T 1 , 23?5
(9) at T 3 and 24 (90) at T 5 . All comparisons were non-signi¢cant. Pulmonary function tests, performed on the fourth day of the admission, revealed moderate air£ow obstruction. Mean (SD) FEV 1 was 45715% predicted and the mean (SD) forced vital capacity (FVC) was 59 (12)% predicted.
All subjects enrolled in this study recovered from their acute exacerbation of COPD. Symptoms subsided promptly, and patients were discharged after a mean (SD) hospital stay of 7 (2) days. After discharge, patients were telephoned every 2 weeks, to gain information about their condition and adherence to treatment. In particular, oral corticosteriods were withdrawn from all subjects within 3 weeks after discharge.
At the follow-up appointment, 60 days after discharge, all subjects were in stable clinical condition and none had experienced a further episode of acute exacerbation, as determined by the questionnaire. Pulmonary function tests showed a mean (SD) FEV 1 of 57?8 (16)% predicted and a mean (SD) FVC of 73 (13)% predicted.The di¡erence in FEV 1 values between exacerbation and follow-up was highly signi¢cant (P=0 Á 00001).
The mean (SD) urinary excretion of DES, as determined at T 60 , was 20?9 (7) mg g -1 creatinine. The di¡er-ence between T 60 and the mean of the three values obtained during the exacerbation was statistically significant (P= 0?049). Figure 1 shows a plot of urinary excretion of DES and of FEV 1 during the study period.
DISCUSSION
Emphysema is one of the critical elements for de¢ning COPD. Although the precise details of the events in the alveolar walls are poorly understood, there are three main hypotheses of its pathogenesis. These are more
FIG. 1. Time course of desmosine (^^^) and FEV 1 (^^). Points represent mean values (SD).
The shaded area represents the mean71 Á96 SD of urinary DES in 12 healthy never-smokers (4) . Note that meanvalues of DESinthis study are above the range of normal at alltime points.Values ony-axis are mg g -1 for DES and % predicted for FEV 1 overlapping than exclusive and include the elastase^anti-elastase imbalance hypothesis (1), the oxidant^anti-oxidant imbalance hypothesis (9) and the infection hypothesis (10) .This study does not specify between these three hypotheses. It suggests that excess elastin degradation occurs in an acute exacerbation of COPD because of increased in£ammation in the lungs. Elastin degradation could be due to elastase^anti-elastase imbalance, to oxidant^anti-oxidant imbalance in the lungs or to infection; we do not distinguish among in£ammation due to viruses, bacteria or chemical irritation, as from urban air pollution.
Previous studies have shown that urinary DES is elevated in subjects with COPD in comparison to both never-smokers and smokers without air£ow obstruction (3). Note in Fig.1that mean values of DES in this study are above the range of normal at all time points.We hoped in the current study to determine whether elastin degradation was increased during an acute exacerbation of COPD as compared with the stable state. Accordingly, we measured cross-link excretion during the acute phase of an acute exacerbation (days 1^5). Since baseline urinary DES values were not available on our subjects, we assumed that urinary DES/IDES excretion during the chronic phase (day 60) would be a reasonable re£ection of the pre-exacerbation, stable state.We also measured the FEV 1 during the acute and late phases of the study. We reasoned that the FEV 1 would be decreased during the acute phase of the study as a result of increased in£ammation in the lungs and should be restored during the chronic phase as the in£ammation accompanying the exacerbation subsided. Two recent reports support the behaviour of the FEV 1 in this condition. Hill et al. (11) compared 11 patients with homozygous AAT de¢ciency and 11 control patients with COPD and normal AAT levels during an exacerbation. All patients received14 days of antibiotic therapy; none received oral corticosteroids. The concentrations of sputum myeloperoxidase activity (which served as an assessment of neutrophil in£ux), sputum elastase activity, IL-8 and LTB 4 concentrations all fell signi¢cantly by the third day of the exacerbation and had reached a nadir by day 14. At presentation, sputum elastase acivity, IL-8 and LTB 4 concentrations were lower in the control COPD patients than in the AAT-de¢cient COPD patients; the time course of improvement was similar in the two groups. In the AAT-de¢cient group, mean (SE) peak expiratory £ow rate was 236?4 (41?4) l min -1 at presentation and rose by 11?9 per cent of baseline (Po0?005) by day 14. Peak £ow rate results were similar in the usual COPD group.
Bhowmik et al. (12) studied ventilatory function, sputum cells and cytokines in 57 patients with moderate to severe COPD during the stable state and during an exacerbation of their disease. Median values of IL-6, IL-8, total cell count, total neutrophils, total eosinophils and total lymphocytes were higher during exacerbation than in the stable state, but the only signi¢cant di¡erence (Po0?05) was for IL-6. The mean (SD) FEV 1 was 1?07 (0?26) I during the stable state and fell to 0?99 (0?31) l (P40?05) at the onset of the exacerbation. The mean peak expiratory £ow rate data, 239 (78) l min -1 and 225 (73) l min -1 , respectively, were statistically signi¢cantly di¡erent (Po0?05).
By 60 days after discharge from hospital, all of our patients showed sustained clinical and functional recovery from the acute exacerbation, as witnessed by the absence of symptoms and marked improvement in FEV 1 . Thus, we have shown in this study that there was a small, but statistically signi¢cant decrease in urinary DES values between the acute and chronic phases of the study and these changes were accompained by an increase in ventilatory function. Hill et al. (11) showed stability of in£ammatory parameters by day 14. Indeed in their data, values of these parameters were higher at day 28 than at day 14.
It is widely accepted that recurrent exacerbations accelerate airway and parenchymal damage in COPD (13), we noted only a modest increase in urinary DES excretion between the acute and chronic phases F3?2 mg g -1 creatinine or 16% of the chronic phase value. However, over a period of years, even slight increases in elastin degradation during an exacerbation may cause a sustained injury. It remains to be determined how long the increase in urinary DES excretion lasts after an exacerbation and whether there is indeed a complete recovery to baseline excretion rate.
Previous papers have failed to demonstrate a correlation between urinary DES levels and FEV 1 measured at a single time point in a group of patients (4, 14) . These observations are not surprising since ventilatory function at any one point in time is determined by the amount of elastin degradation that has occurred in the past over an extended period of timeFa period of years. On the other hand, it makes perfectly good sense that over a period of 2 months after an acute exacerbation of COPD, changes in lung in£ammation, urinary cross-link excretion and ventilatory function should mirror one another.
In mice, after an acute elastolytic injury, more than half of the desmosine-containing peptides removed from the lungs are sequestered by the kidney and then slowly released into the urine over a period of several days (15) . The role of the kidney in the kinetics of elastolysis in stable or acute conditions in humans is undetermined. However, we speculate that in our study, any sequestration of DES in the kidney should have been over by 60 days after the acute exacerbation.
Because of the great expense of evaluating new drugs for COPD using rate of change of FEV 1 as the outcome variable (16) , there is much interest in the possible use of measurement of urinary elastin cross-links as a surrogate marker of elastin degradation in the lungs for drug development in COPD (4, 17, 18) . A recent report failed to demonstrate that short-term AATreplacement therapy in AAT-de¢cient patients was able to reduce elastin breakdown (18) despite baseline elevation of urinary DES levels in these patients. However, the failure of an e¡ect could have been due to a low dose of augmentation therapy with AAT or elastolysis could have been due to macrophage-derived metalloelastase, which is not inactivated by AAT.
The changes in urinary DES between the acute and chronic phases of the study were small and the variability of the DES values is large (coe⁄cient of variation for the six T 1 , T 3 , T 5 and T 60 groups was about 35%). Hence, the data reported here must be considered preliminary and larger studies should be done. Nevertheless, our results raise the question of whether anti-elastase or anti-oxidant drugs might be administered to protect the lungs during an acute excacerbation. While studies of elastases, oxidants or in£ammatory mediators in sputum or bronchoalveolar lavage might be used to determine the e⁄cacy of such drugs, urinary DES measurements are a more de¢nitive measure of lung destruction and should be used as well.
